Article
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.
The Lancet. Oncology - 1 Nov 2012
Ray-Coquard Isabelle, Blay Jean-Yves, Italiano Antoine, Le Cesne Axel, Penel Nicolas, Zhi Jianguo, Heil Florian, Rueger Ruediger, Graves Bradford, Ding Meichun, Geho David, Middleton Steven A, Vassilev Lyubomir T, Nichols Gwen L, Bui Binh Nguyen
Abstract excerpt
BACKGROUND: We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection. METHODS: Patients with well-differentiated or dedifferentiated liposarcoma were enrolled at four centres in France. Patients received up to three 28-day neoadjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.